All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Kocitaf Tablet
Prescription Required
Salt Composition : Dolutegravir,emtricitabine,tenofovir Alafenamide
Manufacturer : MYLAN PHARMACEUTICALS PVT LTD
Origin of Medicine : India
30 Tablet(s) In A Bottle
Introduction to Kocitaf Tablet
Kocitaf Tablet contains the active ingredient Kocitaf Tablet. It is a combination of antiretroviral medication. Dolutegravir belongs to a class of antiretroviral drugs called integrase strand transfer inhibitors (INSTIs). Emtricitabine belongs to the class of medication called nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir alafenamide belongs to the class called nucleotide reverse transcriptase inhibitor (NtRTI). It is combined with other medicines to treat human immunodeficiency virus (HIV-1) infection in adults and adolescents 12 years of age who weigh at least 35kg.
The combination is available as a single tablet regimen, simplifying treatment by reducing the number of pills a person must take daily. This convenience improves medication adherence, ensuring individuals can consistently take their prescribed medication as scheduled. Do not take Kocitaf Tablet if anyone is allergic to it or its components. Get tested for HIV infection regularly while using this medicine. Missing a dose increases the risk of getting HIV infection. This medicine does not prevent other sexually transmitted infections (STIs). Patients should inform the physician if they have liver problems or liver disease, including hepatitis, kidney, and bone problems. This medication is not recommended to give in to children aged 11 years or under.
Uses of Kocitaf Tablet
- HIV infection
Therapeutic Effects of Kocitaf Tablet
Kocitaf Tablet offers a highly effective and convenient treatment for HIV infection. It reduces viral load, maintains long-term viral suppression, and delays disease progression. A single-tablet regimen improves medication adherence. Additionally, it has an improved safety profile with a reduced risk of renal and bone toxicity.
Interaction of Kocitaf Tablet with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products. Certain medications interact with Kocitaf Tablet and reduce their effectiveness by causing undesirable side effects.
More Information about Kocitaf Tablet
- Store this medication below 30°C
- Protect the medicine from light and excessive moisture.
- Keep the medicine out of reach of children and pets
- If you forgot to take the tablet, take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.
How to consume Kocitaf Tablet
It is an orally available prescription drug. Your doctor will decide the dose and duration of Kocitaf Tablet based on the disease condition and other factors such as body weight and age. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with a glass of water. If you have difficulty in swallowing the tablet whole, you can split it in half after consulting with your doctor.
Safety Advices for Kocitaf Tablet
Pregnancy
There is limited information on the use of Kocitaf Tablet during pregnancy. Inform your physician if you are pregnant or planning to get pregnant during the treatment.
Breast Feeding
Breastfeeding is not recommended in patients taking Kocitaf Tablet because the medicine passes into the breast milk in small amounts and may harm your baby. Do not breastfeed during the treatment.
Lungs
Kocitaf Tablet should be cautiously administered in patients with liver diseases. Dose adjustments are necessary. However, inform your physician of any liver diseases before initiating the therapy.
Liver
It is unknown whether Kocitaf Tablet is safe to be administered in patients with lung diseases. Inform your physician if you have any lung diseases before initiating the therapy.
Alcohol
It is unknown whether Kocitaf Tablet is safe to be administered in patients with lung diseases. Inform your physician if you have any lung diseases before initiating the therapy.
Driving
Kocitaf Tablet can cause dizziness. It is recommended to avoid driving and operating heavy machinery during the treatment.
Side Effects of Kocitaf Tablet
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Serious
- Hepatitis B reactivation
- Increased risk of fracture
- Acute renal failure
Common
- Headache
- Nausea
- Diarrhea
- Fatigue
- Insomnia
Word of Advice
If you are living with HIV or are at risk of contracting the virus, it is crucial to seek medical advice and follow a prescribed treatment plan. Antiretroviral therapy, such as the combination of Kocitaf Tablet, can significantly improve your health outcomes. However, it is essential to remember that medication adherence is key. Consistently taking your prescribed medication as directed by your healthcare provider and attending regular follow-up appointments will help ensure the effectiveness of the treatment and monitor your progress. Additionally, practicing safe sex, using clean needles, and taking preventive measures can significantly reduce the risk of HIV transmission. Remember to consult with healthcare professionals for personalized advice and guidance tailored to your specific needs and circumstances. Do not share needles or other items that may have blood or body fluids on them.
FAQs
Q 1. Can Kocitaf Tablet cure HIV?
Kocitaf Tablet is not a cure for HIV. It is an antiretroviral medication that helps control the virus, reduce its replication, and slow down the progression of the disease. It is essential to continue taking the medication as prescribed, even if you feel well, to maintain viral suppression and protect your immune system.
Q 2. Can Kocitaf Tablet cause changes in cholesterol or blood sugar levels?
Kocitaf Tablet may affect some individuals' cholesterol and blood sugar levels. Regular monitoring of these parameters is recommended, especially in individuals with pre-existing conditions such as diabetes or high cholesterol. Lifestyle modifications or additional treatments may be considered if necessary.
Q 3. Is it safe to abruptly stop taking Kocitaf Tablet?
Abruptly stopping Kocitaf Tablet without medical guidance can lead to viral rebound and a decrease in treatment effectiveness. It is important to consult with your healthcare provider before changing your HIV treatment regimen.
Q 4. Does Kocitaf Tablet affect the liver?
People with liver disease, including chronic hepatitis B or C taking antiretrovirals have a higher risk of severe and potentially fatal liver complications. If you have hepatitis B infection, your doctor will carefully consider the best treatment regimen for you.
Q 5. Can Kocitaf Tablet be used in children and adolescents?
Kocitaf Tablet is approved for use in children and adolescents above a certain age and body weight. The appropriate dosage and safety considerations for pediatric populations should be discussed with a pediatric HIV specialist.
Fact Box of Kocitaf Tablet
Molecule name: Dolutegravir, Emtricitabine, Tenofovir Alafenamide
| Therapeutic class: Anti-retroviral |
Pharmacological class: 1. Dolutegravir: Integrase strand transfer inhibitors 2. Emtricitabine: Nucleoside reverse transcriptase inhibitor 3. Tenofovir Alafenamide: Nucleotide reverse transcriptase inhibitor (NtRTI) | Indications: HIV infection |
References
- Descovy 200 mg/25 mg film coated tablets - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk. Published April 2022. Accessed May 22, 2023. https://www.medicines.org.uk/emc/product/2108/smpc
- Emtricitabine / Tenofovir Alafenamide - Patient | NIH. clinicalinfo.hiv.gov. Published [February 27, 2023].[Accessed May 22, 2023]. https://clinicalinfo.hiv.gov/en/drugs/emtricitabine-tenofovir-alafenamide/patient#dr1
- KD Tripathi, Antiviral Drugs (Anti-retrovirus), Essentials of Medical Pharmacology, 8th Edition, 2019, 860-872.
- Gilead Sciences, Inc., US Food & Drug Administration, [Revised on Sep 2017] [Accessed on 22th Aug 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208215s005lbl.pdf
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
